PEPFAR programs show trends in TB preventive treatment initiation and completion among people with HIVAre more people with HIV getting protection from tuberculosis?

A programmatic report examined trends in tuberculosis preventive treatment among people with HIV across PEPFAR-supported programs in 36 countries. The analysis focused on trends in the initiation and completion of preventive treatment. No comparator group, sample size, follow-up duration, or primary outcome was reported.

Results were limited to descriptive trends for both treatment initiation and completion. No specific numerical data, effect sizes, absolute numbers, p-values, or confidence intervals were provided. The direction of trends and any statistical significance were not reported.

No safety or tolerability data on adverse events, serious adverse events, or treatment discontinuations were included in the report. Key limitations include the absence of a formal study design, lack of quantitative results, and unspecified methodology for trend assessment. The report's descriptive nature precludes causal inference or definitive conclusions about program effectiveness.

For clinical practice, these findings represent program-level observations rather than evidence of intervention efficacy. Clinicians should interpret these trend descriptions cautiously and await studies with specific outcome measures and statistical analysis to inform tuberculosis prevention strategies in this population.